[Differential therapy of heart failure. Which drug for which patient?]

Internist (Berl). 2004 Dec;45(12):1378-87. doi: 10.1007/s00108-004-1290-8.
[Article in German]

Abstract

The implementation of guidelines for medical therapy of heart failure may be problematic for the following reasons: 1. Elderly patients and women were underrepresented in large clinical trials which may limit their therapeutic impact in these patients. 2. Therapeutic decisions are influenced by co-morbidities like renal failure, obstructive airway disease (COLD, Asthma), stroke, and diabetes mellitus. We therefore discuss the differential therapy of heart failure in view of particular patient subgroups.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Clinical Trials as Topic*
  • Decision Support Techniques*
  • Heart Failure / classification
  • Heart Failure / diagnosis*
  • Heart Failure / drug therapy*
  • Humans
  • Patient Selection*
  • Practice Guidelines as Topic*
  • Practice Patterns, Physicians'
  • Risk Assessment / methods*
  • Risk Factors
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors